A large outpatient observational study of patients with atrial fibrillation and chronic kidney disease who were anticoagulated revealed that, compared to warfarin, direct oral anticoagulants exhibited less all-cause mortality and major bleeding with at least equivalent efficacy at preventing stroke.

A large outpatient observational study of patients with atrial fibrillation and chronic kidney disease who were anticoagulated revealed that, compared to warfarin, direct oral anticoagulants exhibited less all-cause mortality and major bleeding with at least equivalent efficacy at preventing stroke.

In a retrospective analysis of electronic health record data matched with remote pacemaker and implantable cardioverter-defibrillator recordings of atrial fibrillation episodes, a threshold daily arrhythmia burden portending higher stroke risk was determined over a range of CHA₂DS₂-VASc scores.

Monotherapy with rivaroxaban was noninferior to combination therapy for the primary efficacy endpoint of composite of stroke, systemic embolism, myocardial infarction, unstable angina, or death from any cause.

Investigators terminated a study early before they could draw any firm conclusions. Thus, there remains a lack of solid evidence to support a firm recommendation regarding optimal blood pressure management for secondary stroke prevention.